Updated results and further follow up from the CaboNivo study with advanced non-clear cell kidney cancer patients were reported at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA this week. There were 40 patients in the study. Most patients had metastatic papillary kidney cancer. Nearly two thirds of patients were previously untreated, while a third of patients had been treated with a targeted therapy.

Nearly half of the patients responded to treatment. The average time to when the treatment stopped working was just over a year (13 months). In half of the patients their cancer had not progressed after one year. In a quarter of patients their cancer had not progressed after 2 years. 70% of patients survived for 18 months and 44% for 3 years. There was no difference in survival for previously treated and untreated patients.

Most patients (88%) reported a side effect, with just over half reporting serious or life-threatening side effects, such as liver damage, high blood pressure and pain. Treatment was stopped in 28% of patients because of side effects.

The results from this study highlight the effectiveness of the combination of cabozantinib plus nivolumab in patients with metastatic non-clear cell kidney cancer, especially metastatic papillary kidney cancer.

Read more in UroToday here